Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 116-123

  Kinney, Gene G ^a   Burno, Maryann ^a   Campbell, Una C ^b   Hernandez, Lisa M ^b   Rodriguez, Dana ^b   Bristow, Linda J ^b   Conn, P Jeffrey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Behavioral Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 HYDROXYPHENYLGLYCINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMPHETAMINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX; STIMULUS RESPONSE;

ANIMALS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENCYCLIDINE; PHENYLACETATES; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0037665283     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.048702     Document Type: Article

References (51)

1. Alagarsamy S, Marino MJ, Rouse ST, Gereau RW, Heinemann SF, and Conn PJ (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234-240.
2. Alagarsamy S, Rouse ST, Junge C, Hubert GW, Gutman D, Smith Y, and Conn PJ (2002) NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol Biochem Behav 73:299-306.
3. 3H]Methoxymethyl-3[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 303:1044-1051.
4. Ango F, Robbe D, Tu JC, Xiao B, Worley FF, Pin JP, Bockaert J, and Fagni L (2002) Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons. Mol Cell Neurosci 20:323-329.
5. Attarian S and Amalric M (1997) Microinfusion of the metabotropic glutamate receptor agonist 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid into the nucleus accumbens induces dopamine-dependent locomotor activation in the rat. Eur J Neurosci 9:809-816.
6. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
7. Benquet P, Gee CE, and Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22:9679-9686.
8. Braff DL and Geyer MA (1990) Sensorimctor gating and schizophrenia: human and animal studies. Arch Gen Psychiatry 47:181-188.
9. Brodkin J, Busse C, Sukoff SJ, and Varney MA (2002) Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone. Pharma-col Biochem Behav 73:359-366.
10. Chavez-Noriega LE, Schaffhauser HJL, and Campbell UC (2002) Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord 1:261-281.
11. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
12. Davis M (1988) Apomorphine, D-amphetamine, strychnine and yohimbine do not alter prepulse inhibition of the acoustic startle reflex. Psychopharmacology 95:151-156.
13. Devon RS, Anderson S, Teague PW, Muir WJ, Murray V, Pelosi AJ, Blackwood DHR, and Porteous DJ (2001) The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 6:311-314.
14. Geyer MA, Dulawa SC, Ralph RJ, and Henry SA (2000) Startle habituation and prepulse inhibition studies in mutant mice. Biol Psychiatry 47:124S.
15. Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154.
16. Goff DC, Tsai G, Manoach DS, and Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
17. Hay M, McKenzie H, Lindsley K, Dietz N, Bradley SR, Conn PJ, and Hasser EM (1999) Heterogeneity of metabotropic glutamate receptors in autonomic cell groups of the medulla oblongata of the rat. J Comp Neurol 403:486-501.
18. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, and Markou A (2002) The mGluR5 antagonist, MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199-1209.
19. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, and Javitt DC (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482.
20. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, and Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
21. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, and Lichenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36.
22. Ishimaru M, Kurumaji A, and Toru M (1992) NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 32:379-381.
23. Ishimaru M, Kurumaji A, and Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 35:84-95.
24. Javitt DC, Sershen H, Hashim A, and Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202-204.
25. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
26. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, and Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
27. Jia Z, Lu YM, Henderson J, Taverna F, Romano C, Abramow-Newerly W, Wojtowicz JM, and Roder J (1998) Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 5:331-343.
28. Johnson MP, Chamberlain M, and Kelly GM (1999) Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists. Brain Res 821:539-545.
29. Khun R, Pagano A, Stoehr N, Vranesic I, Flor PJ, Lingenhöhl K, Spooren W, Gentsch C, Vassout A, Pilc A, et al. (2002) In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. Amino Acids 23:207-211.
30. Kim E, Naisbitt S, Hsueh YP, Rao A, Rothschild A, Craig AM, and Sheng M (1997) GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol 136:669-678.
31. Kinney GG, Wittmann M, Bristow LJ, Campbell UC, and Conn PJ (2002) The mGluR5 receptor antagonist, MPEP, potentiates PCP behavioral effects in rats and mice. Program No. 494.13. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. CD-ROM.
32. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, and Roder JC (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17:5196-5202.
33. Maeda J, Suhara T, Okauchi T, and Semba J (2003) Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex. Neurosci Lett 336:171-174.
34. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, and Conn PJ (2001) Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21:5925-5934.
35. Marino MJ and Conn PJ (2002) Direct and indirect modulation of the N-methyl-D-aspartate receptor: potential for the development of novel antipsychotic therapies. Curr Drug Targets CNS Neurol Disord 1:1-19.
36. Meeker D, Kim JH, and Vezina P (1998) Depletion of dopamine in the nucleus accumbens prevents the generation of locomotion by metabotropic glutamate receptor activation. Brain Res 812:260-264.
37. Moghaddam B, Roth RH, and Bunney BS (1990) Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience 36:669-676.
38. Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, Worley PF, and Sheng M (1999) Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23:569-582.
39. Ohnuma T, Augood SJ, Arai H, McKenna PJ, and Emson PC (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56:207-217.
40. O'Leary DM, Movsesyan V, Vicini S, and Faden AI (2000) Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131:1429-1437.
41. Olney JW, Newcomer JW, and Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatry Res 33:523-533.
42. O'Meara GF, Newman RJ, Reynolds DS, Bristow LJ, and Dawson GR (2002) Behavioural evaluation of mGluR5 knock-out mouse. FENS Abstr 1:A087.6.
43. Pisani A, Calabresi P, Centonze D, and Bernardi G (1997) Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 120:1007-1014.
44. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, and Calabresi P (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106:579-587.
45. Spooren WPJM, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, and Gentsch C (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267-1275.
46. Tatarczyñska E, Kłodziñska A, Chojnacka-Wójcik E, Palucha A, Gasparini F, Kuhn R, and Pilc A (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430.
47. Tsai G, Yang P, Chung L-C, Lange N, and Coyle J (1998) D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
48. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, and Worley PF (1999) Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23:583-592.
49. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, and Worley PF (1998) Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21:717-726.
50. Wong AC, Shetreat ME, Clarke JO, and Rayport S (1999) D1- and D2-like dopamine receptors are co-localized on the presynaptic varicosities of striatal and nucleus accumbens neurons in vitro. Neuroscience 89:221-233.
51. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, Ruggiero A, Lanahan AA, Wenthold RJ, and Worley PF (1998) Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 21:707-716.